DE69327542T2 - Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung - Google Patents

Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung

Info

Publication number
DE69327542T2
DE69327542T2 DE69327542T DE69327542T DE69327542T2 DE 69327542 T2 DE69327542 T2 DE 69327542T2 DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T2 DE69327542 T2 DE 69327542T2
Authority
DE
Germany
Prior art keywords
microsphere
antipsychotic
biocompatible polymer
dispense
microball
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69327542T
Other languages
English (en)
Other versions
DE69327542D1 (de
Inventor
Shigemi Kino
Tomonori Osajima
Hiroaki Mizuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18255017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69327542(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corp filed Critical Welfide Corp
Publication of DE69327542D1 publication Critical patent/DE69327542D1/de
Application granted granted Critical
Publication of DE69327542T2 publication Critical patent/DE69327542T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
DE69327542T 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung Revoked DE69327542T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33244192 1992-11-17
PCT/JP1993/001673 WO1994010982A1 (en) 1992-11-17 1993-11-15 Sustained-release microsphere containing antipsychotic and process for producing the same

Publications (2)

Publication Number Publication Date
DE69327542D1 DE69327542D1 (de) 2000-02-10
DE69327542T2 true DE69327542T2 (de) 2000-07-06

Family

ID=18255017

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69327542T Revoked DE69327542T2 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.

Country Status (11)

Country Link
US (2) US5656299A (de)
EP (1) EP0669128B1 (de)
KR (1) KR100333115B1 (de)
AT (1) ATE188375T1 (de)
CA (1) CA2148823C (de)
DE (2) DE69327542T2 (de)
DK (1) DK0669128T3 (de)
ES (1) ES2077547T3 (de)
GR (2) GR960300020T1 (de)
PT (1) PT669128E (de)
WO (1) WO1994010982A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
ES2172574T5 (es) * 1993-11-19 2012-11-29 Alkermes, Inc. Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
EP0733368A1 (de) * 1995-03-24 1996-09-25 Eli Lilly And Company Granulatformulierungen von Olanzapin
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
ATE357218T1 (de) * 1996-05-07 2007-04-15 Alkermes Inc Micropartikel
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
EP0839525B1 (de) * 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter Freisetzung
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6854841B1 (en) * 1998-04-17 2005-02-15 Elesys, Inc. Point-of-incidence ink-curing mechanisms for radial printing
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
GB9817078D0 (en) * 1998-08-05 1998-10-07 Habib Nagy A Device for liver surgery
UA66872C2 (uk) * 1998-09-30 2004-06-15 Елі Ліллі Енд Компані Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
AU768527B2 (en) * 1999-02-23 2003-12-18 Angiotech International Ag Compositions and methods for improving integrity of compromised body passageways and cavities
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
AU2002233239B2 (en) * 2000-12-13 2006-05-11 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
BR0210722A (pt) 2001-06-29 2004-07-20 Medgraft Microtech Inc Implantes injetáveis biodegradáveis e métodos relacionados de produção e uso
EP1275378B1 (de) 2001-07-10 2009-04-15 Canon Kabushiki Kaisha Partikel auf Basis von Polyhydroxyalkanoat und Verfahren zu deren Herstellung
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US6699963B2 (en) * 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
EP2087882A1 (de) * 2002-03-26 2009-08-12 Teva Pharmaceutical Industries Ltd. Arzneimittelmikropartikel
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1595549A4 (de) * 2003-02-19 2010-09-22 Takeda Pharmaceutical Dispergens für zubereitungen mit verzögerter freisetzung
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CN1968700A (zh) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
DK1742616T3 (en) * 2004-04-30 2015-01-12 Abraxis Bioscience Llc The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
ITMI20042232A1 (it) * 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
EP1838716B1 (de) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapinpamoat-dihydrat
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2008000573A (es) * 2005-07-18 2008-03-14 Univ Pennsylvania Implantes que contienen farmacos y metodos de uso de los mismos.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
CL2007002851A1 (es) * 2006-10-05 2008-01-18 M S Panacea Biotec Ltd Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
CA2764960C (en) 2009-06-09 2017-07-18 Neuronano Ab Microelectrode and multiple microelectrodes
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PT3566696T (pt) 2011-04-25 2021-01-11 Nanjing Luye Pharmaceutical Co Ltd Composição de microesfera para libertação sustentada de risperidona
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
CN115804749A (zh) 2013-03-11 2023-03-17 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
KR101738127B1 (ko) * 2014-08-08 2017-05-22 (주)비씨월드제약 약물 함유 서방성 미립자의 제조 방법
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
CN114126592A (zh) * 2019-07-12 2022-03-01 G2G生物公司 含有利凡斯的明的长效制剂及其制备方法
CN111991397B (zh) * 2020-10-13 2021-09-10 深圳善康医疗健康产业有限公司 一种氟哌噻吨美利曲辛微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
FR2534139B1 (fr) * 1982-10-07 1986-08-29 Laruelle Claude Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
CA2148823A1 (en) 1994-05-26
EP0669128A1 (de) 1995-08-30
US5656299A (en) 1997-08-12
GR960300020T1 (en) 1996-03-31
ES2077547T1 (es) 1995-12-01
EP0669128B1 (de) 2000-01-05
WO1994010982A1 (en) 1994-05-26
ATE188375T1 (de) 2000-01-15
DE669128T1 (de) 1996-03-14
ES2077547T3 (es) 2000-06-16
PT669128E (pt) 2000-06-30
DK0669128T3 (da) 2000-06-19
DE69327542D1 (de) 2000-02-10
KR100333115B1 (ko) 2002-12-02
CA2148823C (en) 1999-03-09
US5871778A (en) 1999-02-16
GR3033016T3 (en) 2000-08-31
EP0669128A4 (de) 1996-09-25
KR950703936A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
DE69327542T2 (de) Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
Devlin et al. Healing of tooth extraction sockets in experimental diabetes mellitus
RU2207350C2 (ru) Способные подвергаться биологической деструкции полимеры, цепи которых удлинены фосфатами, композиции, изделия, способы их получения и использования
DE69819694T2 (de) Subkutan oder intradermal injizierbares implantat in der plastischen oder wiederherstellenden chirurgie
DE3778244D1 (de) Oestradiol-implantat und verfahren zu seiner herstellung.
IL78826A0 (en) Sustained release pharmaceutical compositions incorporating degradable delivery system of drugs
EP0301856A3 (en) Delivery system
YU31582A (en) Process for preparing a heterogeneous coplymere of lactic and glycolic acid units
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
ATE125158T1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
IE882727L (en) Sustained release pharmaceutical compositions
KR960705512A (ko) 생체적합성 안과용 삽입체(biocompatible ocular implants)
ATA154590A (de) Verfahren zur herstellung einer pharmazeutischen zubereitung in form von mikropartikeln zur herstellung von injizierbaren suspensionen zur verzoegerten und kontrollierten abgabe eines peptids
ATE196093T1 (de) Fibrin oder fibrinogen sowie biologisch abbaubare und biokompatible polymere enthaltende zusammensetzung zur gewebebehandlung
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
FR2686250B1 (de)
DE69703430D1 (de) Polymere mit kontrolliertem physikalischen zustand und bioerodierbarkeit
DE3889933D1 (de) Perorale Arzneimittelzubereitung mit verzögerter Wirkstofffreigabe.
DO et al. Optimizing Injections of Poly–L–Lactic Acid: The 6-Step Technique
JPS6450824A (en) Improved immunity for mammals

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: WELFIDE CORP., OSAKA, JP

8327 Change in the person/name/address of the patent owner

Owner name: MITSUBISHI PHARMA CORP., OSAKA, JP

8331 Complete revocation